PO.TB10.02 · 肿瘤生物学

Immunomodulatory PIGR + RORC + dendritic cells (PRDCs) are enriched in malignant ascites

海报缩略图:Immunomodulatory PIGR + RORC + dendritic cells (PRDCs) are enriched in malignant ascites
编号 6134 展板 25 时间 4/21 02:00–05:00 区域 Section 28 主讲 Steven Blum, MD
分会场 Metastasis and Organ-Specific Microenvironmental Evolution
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Steven M. Blum1, Thomas L. Chan1, Neal P. Smith1, Courtney Ambrose1, Katherine H. Xu1, Alice Tirard1, Nandini Samanta1, Sidney Martin1, Roya Best1, Elizabeth Tuttle1, Christopher T. Stueber1, Vaishnavi R. Yalala1, Haley Barnes1, Sean T. Bannon1, Yuhui Song1, Benjamin Y. Arnold1, Mushriq Al-Jazrawe2, Joseph J. Zhao3, Kamil Slowikowski1, Jessica Tantivit1, Kasidet Manakongtreecheep1, Lukas M. Altenburger1, Simon Knott4, Matthew R. Strickland1, Michael G. Drage1, Linda T. Nieman1, Jesse S. Boehm2, Raghav Sundar5, Gary Reynolds1, Samuel J. Klempner1, Alexandra-Chloé Villani1

1Massachusetts General Hospital, Boston, MA,2Koch Inst. for Integrative Cancer Research at MIT, Cambridge, MA,3Yong Loo Lin School of Medicine, Singapore, Singapore,4Cedars-Sinai Medical Center, Los Angeles, CA,5Yale University School of Medicine, New Haven, CT

摘要 Abstract

Background : Peritoneal carcinomatosis and malignant ascites are frequently caused by solid tumors, and the presence of ascites is associated with a poor prognosis and resistance to immune checkpoint inhibitors. While some immunosuppressive features of ascites have been described, the role of dendritic cell (DC) subsets in this microenvironment is unknown. Recently, a subset of DCs that express RORC have been found in normal mouse and human tissues, and they have been linked to tolerance of gut antigens. However, this DC population has not previously been associated with cancer or well characterized in humans. Methods : We performed single-cell RNA sequencing (scRNA-seq) with paired surface proteomics (CITE-seq), and secreted proteomics (n = 109 analytes) on ascites (n = 23) and matched peripheral blood (n = 15) from patients with gastric and gastroesophageal adenocarcinoma (GEA; n = 523,322 total cells). Allogeneic mixed lymphocyte reactions (MLRs) were performed using DCs from GEA and pancreas cancer patients with ascites. In vitro differentiation experiments leveraged cDCs from healthy donors and cultured them in media supplemented with ascites supernatant or paired plasma from GEA patients. Results : We identified a DC subset expressing PIGR and RORC (PRDCs) that were transcriptionally distinct from canonical DC subsets and similar to tolerogenic cell subsets. Analysis of >1x10 7 cells from public datasets suggest that PRDCs are found in other human tissues but enriched in malignant ascites from both GEA and ovarian cancers. Sorted PRDCs stimulated T-cell proliferation in MLRs. However, scRNAseq of T cells stimulated by PRDCs showed that those T cells were less effectively polarized due to reduced expression of effector cytokine genes ( e.g. , IFNG , IL5 , IL13 ) compared to T cells stimulated by cDC2s. Spatial transcriptomics confirmed the presence of PRDC-like cells in human lymphoid tissues, and neighboring, proliferating CD4 T cells similarly showed reduced polarization signatures. Features of the PRDC transcriptional program could be induced by culturing blood-derived cDC1s from healthy donors in supernatant from patients with malignant ascites, suggesting that PRDCs are induced in the ascites microenvironment. Conclusions : PRDCs represent a conserved, immunomodulatory DC subset enriched in malignant ascites. PRDCs are capable of modulating T-cell responses and may represent a tolerogenic state induced by the ascites microenvironment. Targeting PRDCs or their differentiation pathways may offer new strategies to enhance anti-tumor immunity in patients with peritoneal metastases.
利益披露 Disclosure
S. M. Blum, None.. T. L. Chan, None.. N. P. Smith, None.. C. Ambrose, None.. K. H. Xu, None.. A. Tirard, None.. N. Samanta, None.. S. Martin, None.. R. Best, None.. E. Tuttle, None.. C. T. Stueber, None.. V. R. Yalala, None.. H. Barnes, None.. S. T. Bannon, None.. Y. Song, None.. B. Y. Arnold, None.. M. Al-Jazrawe, None.. J. J. Zhao, None.. K. Slowikowski, None.. J. Tantivit, None.. K. Manakongtreecheep, None.. L. M. Altenburger, None.. S. Knott, None. M. R. Strickland, Astellas Pharma Independent Contractor. Bristol Myers Squibb Independent Contractor. AstraZeneca Independent Contractor. M. G. Drage, None.. L. T. Nieman, None.. J. S. Boehm, None. R. Sundar, Bristol Myers Squibb ). Merck ). Eisai ). Bayer ). Taiho ). Novartis ). Eli Lilly ). Roche ). AstraZeneca ). Paxman Coolers ). Merck Sharp & Dohme ). Natera ). Astellas ). GlaxoSmithKline ). Ipsen ). Pierre - Fabre ). Tavotek ). Sanofi ). Daichii Sankyo ). Beigene ). G. Reynolds, None. S. J. Klempner, Astellas Independent Contractor. Merck Independent Contractor. AstraZeneca Independent Contractor. Gilead Independent Contractor. Eisai Independent Contractor. Taiho Oncology Independent Contractor. Daiichi - Sankyo Independent Contractor. Amgen Independent Contractor. A. Villani, Bristol Myers Squibb Independent Contractor. Merck Independent Contractor.

在会议检索中打开